Antistasin is a 119-amino acid protein initially isolated from salivary glands of the Mexican leech, Haementeria officinalis, that exhibits potent anticoagulant properties resulting from selective inhibition of blood coagulation factor Xa. The comparative antithrombotic efficacies of recombinant antistasin (rATS), standard heparin (Hep), and aspirin (ASA) administered adjunctly with recombinant tissue-type plasminogen activator (tPA) on thrombolytic reperfusion and reocclusion were determined in a canine model of femoral arterial thrombosis. An occlusive thrombus was formed by insertion of a thrombogenic copper coil into the femoral artery, and blood flow velocity was monitored directly and continuously by Doppler flowmetry. Sixty minutes after occlusion, dogs received an intravenous infusion of either saline (vehicle) or rATS (0.31, 1.25, or 2.5 p,g/kg/min), intravenous boluses of Hep (100 units/kg+50 units/kg/hr or 200 units/kg+150 units/kg/hr), or a single intravenous bolus of ASA (2.0 mg/kg), followed 45 minutes later by tPA (0.8 mg/kg i.v. over 90 minutes). The saline and rATS infusions were discontinued 60 minutes after termination of tPA, and the last Hep boluses were given 105 minutes after termination of tPA. All dogs achieved reperfusion. The time to reperfusion in the ASA group was similar to that in the vehicle group (50+9 versus 50±6 minutes, respectively). Reperfusion times were slightly decreased by the low and high doses of Hep (34±6 and 31±4 minutes, respectively) and the rATS doses of 0.31 and 1.25 ,ug/kg/min (37±4 and 36±5 minutes, respectively). However, the time to reperfusion was dramatically reduced with the 2.5 pg/kg/min rATS dose (15±3 minutes, p<0.05). After termination of the tPA, the femoral arteries of all vehicle-treated dogs reoccluded within 24±2 minutes. Reocclusion was unaffected by ASA (30±6 minutes) and slightly delayed with low-dose Hep (52± 12 minutes). High-dose Hep decreased the incidence of (four of eight) and prolonged the time to (83±24 minutes) reocclusion with an associated elevation in the activated partial thromboplastin time to 8.3-fold control. In stark contrast, reocclusion was prevented in all dogs both during rATS infusions and 2 hours after they were terminated. rATS caused a dose-dependent elevation in the activated partial thromboplastin time, resulting in clotting times 1.8-, 2.9-, and 3.9-fold control at doses of 0.31, 1.25, and 2.5 pg/kg/min, respectively. Slight elevations in bleeding time (.1.6-fold) were observed with high-dose Hep and rATS at doses of 1.25 and 2.5 /&g/kg/min.
Mellott et al Efficacy of Factor Xa Inhibition in Arterial Thrombosis 1153 models through the use of monoclonal antibodies and small Arg-Gly-Asp-containing peptides and proteins derived from snake venoms that block the platelet glycoprotein lIb/llla receptor complex.20-27 The contributing role of thrombin in the formation of arterial thrombi had been questioned on the basis of the limited efficacy of heparin in the prevention of these phenomena. However, the more recent analysis of small, direct, and highly selective thrombin inhibitors including hirudin, a tripeptide chloromethyl ketone (PPACK), and MCI-9038 (Argatroban Genentech, South San Francisco, Calif.) has demonstrated the utility of direct thrombin inhibition in preventing platelet-mediated arterial thrombosis. [28] [29] [30] [31] [32] [33] Although both of these approaches have demonstrated efficacy in preventing thrombus formation, they are associated with impairment of normal hemostasis as reflected by a significant prolongation of template bleeding time and/or coagulation time. The recent demonstration of the antithrombotic efficacy of activated recombinant protein C in a baboon model of arterial thrombosis suggests that interruption of the coagulation cascade by selective inhibition of thrombin generation rather than inhibition of preformed thrombin may prevent intravascular thrombosis without compromising normal hemostasis. 34 Activation of the coagulation cascade via either the intrinsic or extrinsic branches results in the formation of factor Xa. Factor Xa in combination with its cofactor Va and calcium then assembles into a prothrombinase complex on an appropriate phospholipid surface and catalyzes the formation of thrombin from prothrombin. The central position of factor Xa in the coagulation cascade makes it an attractive target for pharmacological intervention. Antistasin is a 119-amino acid protein initially isolated from salivary glands of the Mexican leech, Haementeria officinalis. 35, 36 It exhibits potent anticoagulant properties resulting from the stoichiometric and highly selective inhibition of factor Xa. 37 In this study we compared the effects of recombinant antistasin (rATS),38'39 Hep, and ASA on tissue-type plasminogen activator (tPA)-induced reperfusion and acute reocclusion in a canine model of femoral arterial thrombosis. The results demonstrate that rATS significantly accelerated reperfusion as compared with Hep and ASA and completely prevented acute reocclusion at plasma concentrations that did not impair primary hemostasis.
Materials and Methods

Experimental Protocol
Sixty-four adult mongrel dogs of either sex weighing [7] [8] [9] [10] kg were used in the study. The dogs were anesthetized with sodium pentobarbital (35 Hep (sodium injection, USP; Upjohn Co., Kalamazoo, Mich.) was prepared from a stock solution of 1,000 units/ml. ASA (acetylsalicylic acid; Sigma Chemical Co., St. Louis, Mo.) was initially dissolved in 1.0 ml ethanol, diluted with 2.0 ml of 50 mM Tris buffer (pH 9.4), and brought to a final volume of 10.0 ml with saline.
Hematological Evaluations
Four milliliters of arterial blood was withdrawn into a plastic syringe containing 0.4 ml of 3.8% trisodium citrate solution. The blood was centrifuged at 5°C for 10 minutes at 2,000g. The plasma was removed and stored on ice for immediate assay or frozen at -70°C. The APTI was determined with an automated APTT kit (Organon Teknika Corp., Durham, N.C.). Buccal mucosa bleeding times were measured with a Simplate bleeding time device (Organon Teknika), as previously described.4' Whole-blood platelet counts were determined on a Series 9000 blood analyzer (Serona Baker, Allentown, Pa.).
Plasma Recombinant Antistasin Concentrations
Plasma rATS levels were measured using a purified human factor Xa chromogenic substrate-based assay and a standard curve constructed from purified rATS dilutions made up in control, preinfusion plasma as described previously.39g42
Exc Vivo Platelet Aggregation
Arterial blood was withdrawn into a plastic syringe containing one part 3.8% trisodium citrate to nine parts blood. Platelet-rich plasma was obtained by centrifuging the blood at 150g for 15 minutes. Platelet counts were adjusted to 300,000/mm3 with platelet-poor plasma. The platelet-rich plasma samples were primed with epinephrine (final concentration, 1 ,M) 1 minute before the agonist was added. Aggregation to ADP (BioData, Hatboro, Pa.; 2.5, 5.0, and 10.0 ,M) and arachidonic acid (BioData; 100, 250, 500, and 1,000 ,uM) was measured as a percent change in light transmission.
Reperfusion and Reocclusion
The time to reperfusion was defined as the reestablishment of FABFV to at least 50% of control "coil" FABFV (FABFV measured immediately after placement of the coil) for a period of 5 minutes or any measurable continuous flow for 15 minutes after the tPA infusion was started. The time to reocclusion was defined as the first incidence of FABFV returning to zero flow after the tPA infusion was stopped.
Statistical Analysis
Results are expressed as the mean+SEM. 
Results
Arterial Reperfusion and Reocclusion
After insertion of the copper coil, an occlusive thrombus was formed in all dogs in all groups in 9.1±0. (Figures 2 and 3) . reflecting the complete prevention of reocclusion after the tPA infusion was terminated ( Figure 3 ). 
Hemodynamics
Changes in mean arterial blood pressure and heart rate throughout the experimental period are shown in In addition to the above process of thrombin protection, the Hep may be subjected to inactivation by endogenous inhibitors such as platelet factor 4, which may limit its effectiveness as an adjunct to thrombolytic therapy. 55 In contrast to Hep and ASA, rATS administered as a continuous infusion of 2.5 ,ug/kg/min significantly reduced the time to tPA-induced reperfusion. This probably reflects the ability of rATS to limit clot extension by inhibiting continued thrombin generation and thus fibrin and platelet deposition at the site of the growing thrombus. Furthermore, thrombin activates factor XIII, which catalyzes the covalent cross-linking of fibrin, thereby increasing its resistance to lysis.56-58 Inhibition of thrombin generation would prevent the factor XIIIamediated cross-linking and possibly contribute to accelerated tPA-induced thrombolysis. All three doses of rATS administered in this study completely inhibited acute reocclusion in 100% of the dogs during the rATS infusions and for 120 minutes after they were terminated. This is reflected most dramatically by the complete maintenance of FABFV throughout the experimental protocol as well as an 80% reduction in final clot weights. The antithrombotic efficacy of rATS is attributed to the inhibition of factor Xa in the prothrombinase complex since rATS exhibits no detectable inhibition of thrombin. 37 These results demonstrate that the principal mechanism of reocclusion after thrombolysis in this model is the continuous generation of new thrombin and not reexposure of preformed, clot-bound thrombin. Inhibition of thrombin generation may eliminate the strong, thrombin-mediated positive-feedback activation of factors V and VIII. 59 This would result in reduced prothrombinase activity and might suppress the burst of thrombin that is thought to occur after activation of the coagulation cascade. 60 The profound effects of rATS on reocclusion probably reflect its long circulating half-life. This is suggested by the slow rate of depletion of plasma rATS levels as well as the sluggish return of APTT values toward baseline after termination of the rATS infusions. Although we have not determined the clearance rate of rATS in the dog, preliminary results in the rhesus monkey suggest a circulating half-life approaching 10-12 hours (C.T. Dunwiddie, unpublished data). Therefore, because of the slow clearance rate of rATS and the relatively short observation period (120 minutes) inherent to acute animal models like the one used here, we are unable to determine whether the prolonged antithrombotic properties exhibited by rATS simply reflect a pharmacokinetic effect unique to this molecule or a mechanistic advantage of factor Xa inhibition over thrombin inhibition. This question is currently under investigation by using thrombosis models more amenable to long observation periods after termination of adjunctive therapies. Nonetheless, the lowest infusion dose of rATS, which reaches peak levels of only 29 nM in the plasma, is fully effective in preventing reocclusion for the full 2-hour observation period.
A variety of antiplatelet agents that block the platelet glycoprotein lIb/llla complex, like the highly selective, direct thrombin inhibitors mentioned above, have demonstrated antithrombotic efficacy in many animal models of thrombosis.20-27 Although both approaches prevent thrombus formation, they are associated with an impairment of normal hemostasis as reflected by a significant prolongation in the bleeding time. A recent study in a primate model of occlusive thrombus formation has demonstrated antithrombotic effects without compromising primary hemostasis with the administration of activated recombinant protein C. 34 Likewise, rATS, at a dose that completely prevented reocclusion, resulted in maximal elevations in bleeding time and APTT of only 1.2-fold and 1.8-fold control, respectively. These results suggest that inhibition of thrombin generation rather than direct inhibition of preformed thrombin may be fully antithrombotic without the associated effects on primary hemostasis.
The pronounced antithrombotic effects exhibited by rATS clearly implicate thrombin generation as a major source of thrombin activity during thrombolysis in this model. However, two limitations of this thrombolytic model require prudence when one attempts to extrapolate the beneficial results reported here to the clinical situation. First, this canine model uses a normal femoral artery rather than an atherosclerotic coronary artery, and second, adjunctive treatments were initiated after a 60-minute period of clot maturation rather than the 3-6-hour delay that occurs clinically.
In conclusion, the potent and selective factor Xa inhibitor rATS has been shown to significantly accelerate tPA-induced thrombolysis and 
